Wakefit Innovations Ltd
WAKEFITWakefit Innovations Ltd is strength at full price. The numbers are improving — and a P/E at the 87th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 87th percentile of its own range you are paying full price for it.
The price is in a downtrend (32 weeks in) while the P/E sits at the 87th percentile of its own 0-year range. Underneath, the last four quarters read improving. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Wakefit Innovations Ltd trades at ₹130, in a downtrend and 32 weeks into that stage. That is −17.0% against its own 200-day average. It sits at 15% of a 52-week range of ₹115 to ₹213. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 32 of stage 4, confirmed. At ₹130 it trades −17.0% versus its 200-day average and sits at 15% of its 52-week range (₹115–₹213).
Against the market, two honest reads. Cumulative: over the last 7 months the stock moved −33% while the NIFTY 500 moved −4% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 87th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Wakefit Innovations Ltd trades at 22.3× P/E, at the pricey end of its own range (87th percentile). Its long-run median P/E is 21.3×, measured across 0.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.3× is at the pricey end of its own range (87th percentile), against a long-run median of 21.3× measured over 0.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Wakefit Innovations Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.9% | +22.3% | +29.5% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
54.3/100 — rank 2 of 2 in Mattress · 39% evidence confidence · provisional, ranked below fully-evidenced peers
Wakefit Innovations Ltd scores 54.3 out of 100 against the 2 companies it is compared with in Mattress, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 23.1 + 11.2 + 10 + 10 = 54.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Wakefit Innovations Ltd reported ₹344 Cr of revenue in the Mar 26 quarter, +13.5% year on year. That is the 2nd straight quarter of year-on-year growth. Over 5 years it has compounded at 29.5% a year. The last full year, FY26, came in at ₹1,489 Cr. The last four reported quarters add to ₹1,445 Cr.
Wakefit Innovations Ltd reported ₹344 Cr of revenue in the Mar 26 quarter, +13.5% year on year. That is the 2nd straight quarter of year-on-year growth. Over 5 years it has compounded at 29.5% a year. The last full year, FY26, came in at ₹1,489 Cr. The last four reported quarters add to ₹1,445 Cr.
FY26 revenue came in at ₹1,489 Cr (+16.9% on the year), capping 5 years at 29.5% compound. The latest quarter (Mar 26) printed ₹344 Cr, +13.5% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +11.4% growth against the decade's 29.5% — the current year is running slower than its own long-run rate.
→ Revenue grew — did margins hold as it scaled? Next: 11.0% this quarter (+9.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Wakefit Innovations Ltd's operating margin is 11.0% in the Mar 26 quarter, +9.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +6.0 percentage points. Across 6 fiscal years the operating margin has ranged −12.0% to 12.0%.
Wakefit Innovations Ltd's operating margin is 11.0% in the Mar 26 quarter, +9.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +6.0 percentage points. Across 6 fiscal years the operating margin has ranged −12.0% to 12.0%.
The latest quarter's operating margin is 11.0%, +9.0 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −12.0%–12.0%, and FY26's 12.0% is the top of that band — a record year.
Why the margin moved: operating margin went +5.4 pp year on year while gross margin went +4.4 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit null in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Wakefit Innovations Ltd earned ₹122 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹189 Cr. That is 35.5% of the quarter's revenue. The same quarter a year earlier lost ₹2.0 Cr.
Wakefit Innovations Ltd earned ₹122 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹189 Cr. That is 35.5% of the quarter's revenue. The same quarter a year earlier lost ₹2.0 Cr.
Mar 26 profit was ₹122 Cr, null year on year. On the full year, FY26 printed ₹189 Cr (null).
→ Profit rose — but did the cash follow?
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Wakefit Innovations Ltd's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was ₹245 Cr of operating cash against ₹189 Cr of profit. After ₹79.0 Cr of capital spending, ₹166 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of ₹245 Cr against reported profit of ₹189 Cr, leaving free cash of ₹166 Cr after ₹79.0 Cr of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
→ So follow the cash to where it goes. Next: a 2-day cycle and ₹362 Cr of building.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Wakefit Innovations Ltd's cash conversion cycle runs 2 days in FY26, down from 34 days in FY21. Capital spending ran ₹362 Cr over the last 3 years. At FY26 sales of ₹1,489 Cr each day of that cycle holds about ₹4.1 Cr, so roughly ₹8.0 Cr sits inside the business at any moment.
FY26: debtors at 1 days, inventory at 109 days — roughly 3.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 2 days, tighter than FY21's 34.
The full loop: cash goes out to suppliers and production on day 0; stock waits 109 days to sell; customers pay about 1 days after that; and suppliers themselves are paid at 108 days — netting out to the 2-day cycle.
In money terms: at FY26 sales of ₹1,489 Cr, each day of the cycle holds about ₹4.1 Cr — so the 2-day loop keeps roughly ₹8.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹362 Cr over the last 3 fiscal years against ₹264 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 11% and the ROIC − WACC spread is −7.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Wakefit Innovations Ltd earns a ROCE of 11% in FY26. That is up from a trough of −33% in FY22. Return on invested capital clears the cost of that capital by −7.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 12.7% net margin on 0.85× asset turns.
FY26 ROCE is 11%, recovered from a FY22 trough of −33% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 12.7% net margin × 0.85× asset turns × 1.55× balance-sheet leverage ≈ 16.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 4.4% − 12.0% = a −7.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.24.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Wakefit Innovations Ltd carries total debt of ₹272 Cr against shareholder equity of ₹1,132 Cr as of Mar 26, a debt-to-equity of 0.24 — effectively unlevered. On the annual view that ratio went from 0.52 in FY25 to 0.24 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹272 Cr against shareholder equity of ₹1,132 Cr — a debt-to-equity of 0.24. On the annual view, debt-to-equity went from 0.52 (FY25) to 0.24 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: the register is quiet.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Wakefit Innovations Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Wakefit Innovations Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Wakefit Innovations Ltd this page | 22.3× | ₹4,297 Cr | — | — | — | No read |
| Sheela Foam Ltd | 55.3× | ₹8,321 Cr | No read |
Frequently asked questions
What is Wakefit Innovations Ltd's share price today?
Wakefit Innovations Ltd trades at ₹130. The company is valued at ₹4,297 Cr. The stock sits at 15% of its 52-week range of ₹115–₹213, −17.0% versus its 200-day average. On the tape, the price is in a downtrend, 32 weeks in. — as of 24 July 2026.
What were Wakefit Innovations Ltd's latest quarterly results?
Wakefit Innovations Ltd reported revenue of ₹344 Cr and net profit of ₹122 Cr for the Mar 26 quarter. Earnings per share were ₹3.69. The operating margin was 11.0%, 9.0 pp higher than a year earlier. — as of 24 July 2026.
What is Wakefit Innovations Ltd's revenue?
Wakefit Innovations Ltd reported revenue of ₹344 Cr in the Mar 26 quarter, +13.5% year on year. For the full FY26 fiscal year, revenue was ₹1,489 Cr (+16.9%). Over the last 5 years revenue compounded at 29.5% a year. — as of 24 July 2026.
What is Wakefit Innovations Ltd's profit?
Wakefit Innovations Ltd earned ₹122 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹189 Cr. The operating margin ran 11.0% in the latest quarter. — as of 24 July 2026.
What is Wakefit Innovations Ltd's market cap?
Wakefit Innovations Ltd's market capitalisation is ₹4,297 Cr at a share price of ₹130. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Wakefit Innovations Ltd's P/E ratio?
Wakefit Innovations Ltd trades at a P/E of 22.3×, at the 87th percentile of its own 0-year range, against a long-run median of 21.3×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Is Wakefit Innovations Ltd overvalued?
On its own history, Wakefit Innovations Ltd looks expensive against its own history: its P/E of 22.3× sits at the 87th percentile of its 0-year range (long-run median 21.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
How is Wakefit Innovations Ltd performing?
Wakefit Innovations Ltd is in a downtrend, 32 weeks in. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 24 July 2026.
Is Wakefit Innovations Ltd in an uptrend?
No — the price is in a downtrend (week 32 of stage 4), trading −17.0% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Wakefit Innovations Ltd beating the market?
On recent form, yes — Wakefit Innovations Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7 months the stock moved −33% against the NIFTY 500's −4% — behind the index over the full window. — as of 24 July 2026.
Will Wakefit Innovations Ltd's share price go up?
This page publishes no price forecast for Wakefit Innovations Ltd. What it measures instead: the share price is ₹130, the price is in a downtrend 32 weeks in. Its P/E of 22.3× sits at the 87th percentile of its own 0-year range. — as of 24 July 2026.
Who owns Wakefit Innovations Ltd?
Promoters hold 36.9% of Wakefit Innovations Ltd, foreign institutions 14.5%, domestic institutions 25.9% and the public 22.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 24 July 2026.
Does Wakefit Innovations Ltd have too much debt?
No — Wakefit Innovations Ltd's debt-to-equity is 0.24, and operating profit covers the interest bill 7×. FY26 borrowings were ₹272 Cr against equity of ₹1,132 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Wakefit Innovations Ltd's capex?
Wakefit Innovations Ltd spent ₹362 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹79.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Wakefit Innovations Ltd's cash flow?
Wakefit Innovations Ltd generated ₹245 Cr of operating cash flow in FY26 and ₹166 Cr of free cash flow after ₹79.0 Cr of capital spending. Reported profit that year was ₹189 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Where is Wakefit Innovations Ltd in its business cycle?
Wakefit Innovations Ltd's FY26 operating margin was 12.0%, against a 6-year band of −12.0%–12.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Wakefit Innovations Ltd story?
The sharpest disagreement: the engine is strong, but at the 87th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Wakefit Innovations Ltd a stock worth studying right now?
This is not investment advice. The machine read: Wakefit Innovations Ltd is strength at full price. The numbers are improving — and a P/E at the 87th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.